Single-vector, single-injection recombinant vesicular stomatitis virus vaccines against high-containment viruses

Michael A. Whitt, Thomas Geisbert, Chad Mire

Research output: Chapter in Book/Report/Conference proceedingChapter

10 Citations (Scopus)

Abstract

There are many avenues for making an effective vaccine against viruses. Depending on the virus these can include one of the following: inactivation of whole virions; attenuation of viruses; recombinant viral proteins; non-replication-competent virus particles; or surrogate virus vector systems such as vesicular stomatitis virus (VSV). VSV is a prototypic enveloped animal virus that has been used for over four decades to study virus replication, entry, and assembly due to its ability to replicate to high titers in a wide variety of mammalian and insect cells. The use of reverse genetics to recover infectious and single-cycle replicating VSV from plasmid DNA transfected in cell culture began a revolution in the study of recombinant VSV (rVSV). This platform can be manipulated to study the viral genetic sequences and proteins important in the virus life cycle. Additionally, foreign genes can be inserted between naturally occurring or generated start/stop signals and polyadenylation sites within the VSV genome. VSV has a tolerance for foreign gene expression which has led to numerous rVSVs reported in the literature. Of particular interest are the very effective single-dose rVSV vaccine vectors against high-containment viruses such as filoviruses, henipaviruses, and arenaviruses. Herein we describe the methods for selecting foreign antigenic genes, selecting the location within the VSV genome for insertion, generation of rVSV using reverse genetics, and proper vaccine study designs.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages295-311
Number of pages17
Volume1403
DOIs
StatePublished - Apr 1 2016

Publication series

NameMethods in Molecular Biology
Volume1403
ISSN (Print)10643745

Fingerprint

Vesicular Stomatitis
Vaccines
Viruses
Injections
Reverse Genetics
Virion
Henipavirus
Arenavirus
Genome
Virus Assembly
Virus Internalization
Polyadenylation
Synthetic Vaccines
DNA Viruses
Viral Proteins
Virus Replication
Life Cycle Stages
Recombinant Proteins
Genes
Insects

Keywords

  • Arenavirus
  • Attachment protein
  • Ebola virus
  • Ferret
  • Filovirus
  • Fusion protein
  • Glycoprotein
  • Guinea pig
  • Henipavirus
  • Immunity
  • Lassa virus
  • Marburg virus
  • Nipah virus
  • Nonhuman primate
  • Single-injection
  • Vaccine
  • Vesicular stomatitis virus

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Whitt, M. A., Geisbert, T., & Mire, C. (2016). Single-vector, single-injection recombinant vesicular stomatitis virus vaccines against high-containment viruses. In Methods in Molecular Biology (Vol. 1403, pp. 295-311). (Methods in Molecular Biology; Vol. 1403). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-3387-7_16

Single-vector, single-injection recombinant vesicular stomatitis virus vaccines against high-containment viruses. / Whitt, Michael A.; Geisbert, Thomas; Mire, Chad.

Methods in Molecular Biology. Vol. 1403 Humana Press Inc., 2016. p. 295-311 (Methods in Molecular Biology; Vol. 1403).

Research output: Chapter in Book/Report/Conference proceedingChapter

Whitt, MA, Geisbert, T & Mire, C 2016, Single-vector, single-injection recombinant vesicular stomatitis virus vaccines against high-containment viruses. in Methods in Molecular Biology. vol. 1403, Methods in Molecular Biology, vol. 1403, Humana Press Inc., pp. 295-311. https://doi.org/10.1007/978-1-4939-3387-7_16
Whitt MA, Geisbert T, Mire C. Single-vector, single-injection recombinant vesicular stomatitis virus vaccines against high-containment viruses. In Methods in Molecular Biology. Vol. 1403. Humana Press Inc. 2016. p. 295-311. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-3387-7_16
Whitt, Michael A. ; Geisbert, Thomas ; Mire, Chad. / Single-vector, single-injection recombinant vesicular stomatitis virus vaccines against high-containment viruses. Methods in Molecular Biology. Vol. 1403 Humana Press Inc., 2016. pp. 295-311 (Methods in Molecular Biology).
@inbook{4fc751c7817c4eb9b9311ee5b96c97f2,
title = "Single-vector, single-injection recombinant vesicular stomatitis virus vaccines against high-containment viruses",
abstract = "There are many avenues for making an effective vaccine against viruses. Depending on the virus these can include one of the following: inactivation of whole virions; attenuation of viruses; recombinant viral proteins; non-replication-competent virus particles; or surrogate virus vector systems such as vesicular stomatitis virus (VSV). VSV is a prototypic enveloped animal virus that has been used for over four decades to study virus replication, entry, and assembly due to its ability to replicate to high titers in a wide variety of mammalian and insect cells. The use of reverse genetics to recover infectious and single-cycle replicating VSV from plasmid DNA transfected in cell culture began a revolution in the study of recombinant VSV (rVSV). This platform can be manipulated to study the viral genetic sequences and proteins important in the virus life cycle. Additionally, foreign genes can be inserted between naturally occurring or generated start/stop signals and polyadenylation sites within the VSV genome. VSV has a tolerance for foreign gene expression which has led to numerous rVSVs reported in the literature. Of particular interest are the very effective single-dose rVSV vaccine vectors against high-containment viruses such as filoviruses, henipaviruses, and arenaviruses. Herein we describe the methods for selecting foreign antigenic genes, selecting the location within the VSV genome for insertion, generation of rVSV using reverse genetics, and proper vaccine study designs.",
keywords = "Arenavirus, Attachment protein, Ebola virus, Ferret, Filovirus, Fusion protein, Glycoprotein, Guinea pig, Henipavirus, Immunity, Lassa virus, Marburg virus, Nipah virus, Nonhuman primate, Single-injection, Vaccine, Vesicular stomatitis virus",
author = "Whitt, {Michael A.} and Thomas Geisbert and Chad Mire",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/978-1-4939-3387-7_16",
language = "English (US)",
volume = "1403",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "295--311",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Single-vector, single-injection recombinant vesicular stomatitis virus vaccines against high-containment viruses

AU - Whitt, Michael A.

AU - Geisbert, Thomas

AU - Mire, Chad

PY - 2016/4/1

Y1 - 2016/4/1

N2 - There are many avenues for making an effective vaccine against viruses. Depending on the virus these can include one of the following: inactivation of whole virions; attenuation of viruses; recombinant viral proteins; non-replication-competent virus particles; or surrogate virus vector systems such as vesicular stomatitis virus (VSV). VSV is a prototypic enveloped animal virus that has been used for over four decades to study virus replication, entry, and assembly due to its ability to replicate to high titers in a wide variety of mammalian and insect cells. The use of reverse genetics to recover infectious and single-cycle replicating VSV from plasmid DNA transfected in cell culture began a revolution in the study of recombinant VSV (rVSV). This platform can be manipulated to study the viral genetic sequences and proteins important in the virus life cycle. Additionally, foreign genes can be inserted between naturally occurring or generated start/stop signals and polyadenylation sites within the VSV genome. VSV has a tolerance for foreign gene expression which has led to numerous rVSVs reported in the literature. Of particular interest are the very effective single-dose rVSV vaccine vectors against high-containment viruses such as filoviruses, henipaviruses, and arenaviruses. Herein we describe the methods for selecting foreign antigenic genes, selecting the location within the VSV genome for insertion, generation of rVSV using reverse genetics, and proper vaccine study designs.

AB - There are many avenues for making an effective vaccine against viruses. Depending on the virus these can include one of the following: inactivation of whole virions; attenuation of viruses; recombinant viral proteins; non-replication-competent virus particles; or surrogate virus vector systems such as vesicular stomatitis virus (VSV). VSV is a prototypic enveloped animal virus that has been used for over four decades to study virus replication, entry, and assembly due to its ability to replicate to high titers in a wide variety of mammalian and insect cells. The use of reverse genetics to recover infectious and single-cycle replicating VSV from plasmid DNA transfected in cell culture began a revolution in the study of recombinant VSV (rVSV). This platform can be manipulated to study the viral genetic sequences and proteins important in the virus life cycle. Additionally, foreign genes can be inserted between naturally occurring or generated start/stop signals and polyadenylation sites within the VSV genome. VSV has a tolerance for foreign gene expression which has led to numerous rVSVs reported in the literature. Of particular interest are the very effective single-dose rVSV vaccine vectors against high-containment viruses such as filoviruses, henipaviruses, and arenaviruses. Herein we describe the methods for selecting foreign antigenic genes, selecting the location within the VSV genome for insertion, generation of rVSV using reverse genetics, and proper vaccine study designs.

KW - Arenavirus

KW - Attachment protein

KW - Ebola virus

KW - Ferret

KW - Filovirus

KW - Fusion protein

KW - Glycoprotein

KW - Guinea pig

KW - Henipavirus

KW - Immunity

KW - Lassa virus

KW - Marburg virus

KW - Nipah virus

KW - Nonhuman primate

KW - Single-injection

KW - Vaccine

KW - Vesicular stomatitis virus

UR - http://www.scopus.com/inward/record.url?scp=84963800067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963800067&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3387-7_16

DO - 10.1007/978-1-4939-3387-7_16

M3 - Chapter

C2 - 27076138

AN - SCOPUS:84963800067

VL - 1403

T3 - Methods in Molecular Biology

SP - 295

EP - 311

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -